Press release content from Business Wire. The AP news staff was not involved in its creation. AstraZeneca to Acquire Alexion, Accelerating the Company’s Strategic and Financial Development December 12, 2020 GMT CAMBRIDGE, England & BOSTON--(BUSINESS WIRE)--Dec 12, 2020-- AstraZeneca and Alexion Pharmaceuticals, Inc. (Alexion) have entered into a definitive agreement for AstraZeneca to acquire Alexion. Alexion shareholders will receive $60 in cash and 2.1243 AstraZeneca American Depositary Shares (ADSs) (each ADS representing one-half of one (1/2) ordinary share of AstraZeneca, as evidenced by American Depositary Receipts (ADRs)) for each Alexion share. Based on AstraZeneca’s reference average ADR price of $54.14, this implies total consideration to Alexion shareholders of $39bn or $175 per share.